Sight Sciences (SGHT) Raises Revenue Forecast as IDE Momentum Grows and Cash Burn Improves

In its second-quarter 2026 release, SGHT showcases a tilting revenue mix toward Interventional Glaucoma (IG) and Interventional Device Exposure (IDE) while nudging the revenue forecast higher and trimming adjusted operating expense guidance. The press materials offer a clean narrative on top-line progress, but they omit explicit EPS figures, leaving readers chasing an EPS consensus and any potential earnings surprise for a later quarter.

Q2 2026 Highlights at a Glance

Ticker: SGHT (Sight Sciences, Inc.)
Revenue (Q2 2026): $23.4 million, up 20% year over year
IG revenue: $20.7 million, up 8% YoY
IDE revenue: $2.7 million, up 704% YoY
IDE patient reach: up to 14.5 million reimbursable lives following payer updates
Cash and equivalents: $79.8 million as of 6/30/2026
Cash usage (Q2 2026): $5.2 million; non-recurring items $3.8 million; tariff refunds $1.6 million
Excluding one-time items: cash usage $1.4 million (down 81% YoY)
Non-recurring item noted: $5.4 million litigation success fee
Strategic note: Raised full-year 2026 revenue forecast; reduced adjusted OPEX guidance
EPS/earnings note: No EPS figure provided in the release; EPS consensus and potential earnings surprise remain to be seen.

A Tale of Two Therapies: IG Steady, IDE Expanding

The quarterly narrative underscores a familiar but meaningful shift: Interventional Glaucoma (IG) continues to contribute solid, steady revenue, while IDE sits on a higher growth trajectory tied to payer policy and reimbursement dynamics. IG revenue of $20.7 million reflects ongoing demand for core interventional technologies, whereas IDE revenue of $2.7 million signals an inflection in payer access and adoption.

The company attributes IDE upside to broader reimbursement alignment, notably following the publication of updated Medicare pricing for CPT code 0563T. The net effect is a meaningful expansion in eligible IDE patients—roughly from 10.4 million to 14.5 million—which could meaningfully support future revenue growth as access translates into utilization.

Cash Flow and One-Time Items: A Candid Review

Sight Sciences ends Q2 with cash and equivalents around $79.8 million. The quarter’s cash usage of $5.2 million benefited from a lower burn rate YoY, but was skewed by non-recurring items, including a $5.4 million litigation success fee and a $3.8 million one-time charge, partially offset by $1.6 million in tariff refunds. Excluding these one-time items, cash usage was $1.4 million, representing an 81% year-over-year improvement.

The takeaway: the company is not simply marching to a higher top line; it is trying to bend the cash curve by isolating one-off costs from ongoing operating dynamics. Investors should watch whether the core cash burn continues to improve as the IDE momentum translates into more durable revenue streams.

Strategic Implications for SGHT and Peers

The double-digit top-line growth in Q2 2026—especially the 704% surge in IDE revenue—suggests the reimbursement ecosystem is becoming an amplifier for adoption, not merely a tailwind. For SGHT, the raised revenue forecast signals a confident view of 2026 trajectory, even as it trims the breadth of its adjusted expense expectations. Analysts lacking an EPS figure in the release will be left to infer whether the improved revenue mix can engender a meaningful earnings per share expansion in the back half of the year.

In terms of the broader ophthalmology and interventional device space, the payer-driven expansion of IDE patient access offers a potential playbook: align pricing and codes, broaden reimbursement—then watch utilization respond. If SGHT’s IDE momentum persists, it could prompt a revaluation of peers whose growth is hamstrung by slower payer progress or less scalable reimbursement frameworks.

Conclusion: A Quarter Shaped by Access, Not Just Subsystems

Sight Sciences’ second quarter reads like a quiet but purposeful acceleration: a healthier revenue forecast, a constructive mix shift toward IDE driven by policy updates, and a cash narrative that looks sturdier once you strip away the one-off charges. The absence of a disclosed EPS figure keeps the market waiting for the traditional earnings surprises and consensus estimates, but the revenue optics and payer dynamics provide a clearer map of where the business could head next.

For SGHT and its sector peers, the moral is less about beating a single quarterly number and more about whether the reimbursement-enabled growth engine can convert expanded patient access into sustainable profitability. If the trend holds, 2026 could be remembered not as a year of dramatic shocks, but as a year when payer policy finally started to stay in the same time zone as patient need.